TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31064757

Group type: EXPERIMENTAL
Intervention: Statin use (defined as two or more fills for a statin during the year after diagnosis)
Number of subjects: 2195

Group type: COMPARATOR
Intervention: Nonusers of statins (control group)
Number of subjects: 2195
Study: 29743051

Group type: EXPERIMENTAL
Intervention: TREAT journal club format
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard journal club format
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both TREAT and Standard formats
Number of subjects: 126
Study: 26726822

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 69
Study: 25304723

Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stem cells (MSCs) from adipose tissue
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (or vehicle)
Number of subjects: 20
Study: 22676723

Group type: EXPERIMENTAL
Intervention: Usual care plus additional physical activity delivered by a physiotherapist or physiotherapy assistant
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Usual care plus additional physical activity
Number of subjects: 47
Study: 20427369

Group type: EXPERIMENTAL
Intervention: 80 mg parecoxib
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 5 g acetaminophen
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 80 mg parecoxib plus 5 g acetaminophen
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 18714736

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 263
Study: 15760498

Group type: EXPERIMENTAL
Intervention: Short limb laparoscopic Roux-en-Y gastric bypass (biliopancreatic limb = 50 cm, alimentary limb = 100 cm)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Long limb laparoscopic Roux-en-Y gastric bypass (biliopancreatic limb = 100 cm, alimentary limb = 150 cm)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Short limb laparoscopic Roux-en-Y gastric bypass
Number of subjects: 48

Group type: COMPARATOR
Intervention: Long limb laparoscopic Roux-en-Y gastric bypass
Number of subjects: 48
Study: 12589613

Group type: EXPERIMENTAL
Intervention: Hip flexor stretching
Number of subjects: 96

Group type: COMPARATOR
Intervention: Shoulder abductor stretching
Number of subjects: 96
Study: 10210023

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM) in combination with Valproic Acid (VPA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Valproic Acid (VPA)
Number of subjects: 13
Study: 8733090

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cardiac surgery
Number of subjects: 63
Study: 1877476

Group type: EXPERIMENTAL
Intervention: Intravenous urokinase plus heparin
Number of subjects: 2531

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 2531

Group type: EXPERIMENTAL
Intervention: Intravenous urokinase plus heparin (anterior infarction subgroup)
Number of subjects: 2531

Group type: COMPARATOR
Intervention: Heparin alone (anterior infarction subgroup)
Number of subjects: 2531

Group type: EXPERIMENTAL
Intervention: Intravenous urokinase
Number of subjects: 2531

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 2531
Study: 6311782

Group type: EXPERIMENTAL
Intervention: mezlocillin (4 g iv 6‐hourly) plus cefotaxime (2 g iv 8‐hourly)
Number of subjects: 54

Group type: COMPARATOR
Intervention: gentamicin (1.5 mg/kg im or iv 8‐hourly) plus cefoxitin (2 g iv 6‐hourly) with metronidazole (500 mg iv 8‐hourly) for anaerobic infections
Number of subjects: 54
Study: 31025050

Group type: EXPERIMENTAL
Intervention: Individualized PAS paradigm (iPAS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Fixed ISI of 25 ms (PAS 25)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Fixed ISI of 22 ms (PAS 22)
Number of subjects: 21
Study: 29246162

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) treatment
Number of subjects: 1224

Group type: EXPERIMENTAL
Intervention: High-risk All CZP patients
Number of subjects: 1224

Group type: EXPERIMENTAL
Intervention: Low-risk All CZP patients
Number of subjects: 1224
Study: 27192215

Group type: EXPERIMENTAL
Intervention: MDD group (n=16)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: MCI group (n=22)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Level of awareness of memory deficits
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: MDD subjects
Number of subjects: 63

Group type: COMPARATOR
Intervention: Clinical controls (n=25)
Number of subjects: 63
Study: 24253534

Group type: EXPERIMENTAL
Intervention: Genetic variants of DPP10, NPSR1, and ADAM33
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Testing cohort (n = 545)
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Replication cohort (n = 502)
Number of subjects: 1047
Study: 23006968

Group type: EXPERIMENTAL
Intervention: Ningdong granule (NDG)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NDG + Haloperidol (Hal)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Haloperidol (Hal)
Number of subjects: 120
Study: 19943331

Group type: EXPERIMENTAL
Intervention: Joint model for longitudinal ordinal measurements and competing risks failure time data using a partial proportional odds model.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Rankin Scale (MRS) as the primary outcome measure.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other ordinal outcomes such as Barthel and Glasgow scales.
Number of subjects: 0
Study: 17627725

Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra), up to one study tablet per day for 6 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 15668624

Group type: EXPERIMENTAL
Intervention: Recreational Music-Making (RMM) activity after a 1-hour stress induction
Number of subjects: 32

Group type: COMPARATOR
Intervention: Resting control group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ongoing stressor group
Number of subjects: 32
Study: 12585141

Group type: EXPERIMENTAL
Intervention: Zhenqi Zhuanyin Decoction (ZQZYD) combined with intrauterine insemination (IUI)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Zhenqi Zhuanyin Decoction (ZQZYD) alone
Number of subjects: 103

Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI) alone
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Zhenqi Zhuanyin Decoction (ZQZYD) and IUI (Group A)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Zhenqi Zhuanyin Decoction (ZQZYD) (Group B)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI) (Group C)
Number of subjects: 103
Study: 10517054

Group type: EXPERIMENTAL
Intervention: Parent and child intervention
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Child-only intervention
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Parent-only intervention
Number of subjects: 62
Study: 8239492

Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg
Number of subjects: 430

Group type: COMPARATOR
Intervention: ranitidine 150 mg bid
Number of subjects: 430
Study: 2905824

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29570538

Group type: EXPERIMENTAL
Intervention: Reboxetine (REB) 8 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study: 27270348

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus leucovorin with oxaliplatin
Number of subjects: 1729

Group type: COMPARATOR
Intervention: Fluorouracil plus leucovorin without oxaliplatin
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus leucovorin with or without oxaliplatin
Number of subjects: 1729
Study: 24912740

Group type: EXPERIMENTAL
Intervention: External cold and vibration via Buzzy
Number of subjects: 176

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 176
Study: 23230096

Group type: EXPERIMENTAL
Intervention: metformin (1.5 g daily)
Number of subjects: 304

Group type: COMPARATOR
Intervention: glipizide (30 mg daily)
Number of subjects: 304
Study: 21624418

Group type: COMPARATOR
Intervention: BioThrax alone
Number of subjects: 69

Group type: COMPARATOR
Intervention: 1 mg of CPG 7909 alone
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: BioThrax plus 1 mg of CPG 7909
Number of subjects: 69
Study: 18177871

Group type: EXPERIMENTAL
Intervention: Myomectomy through ultraminilaparotomy
Number of subjects: 113

Group type: COMPARATOR
Intervention: Myomectomy through laparotomy
Number of subjects: 113
Study: 16394112

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 166310

Group type: EXPERIMENTAL
Intervention: Opposed HRT
Number of subjects: 166310

Group type: EXPERIMENTAL
Intervention: Unopposed HRT
Number of subjects: 166310

Group type: EXPERIMENTAL
Intervention: HRT initiation at different age groups
Number of subjects: 166310

Group type: EXPERIMENTAL
Intervention: Age at MI event
Number of subjects: 166310
Study: 14503803

Group type: EXPERIMENTAL
Intervention: Anthracycline-containing regimens (additive)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Anthracycline-containing regimens (substitutive)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (non-anthracycline regimens)
Number of subjects: 21
Study: 10829042

Group type: EXPERIMENTAL
Intervention: Subcutaneous amifostine 500 mg before each radiotherapy fraction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subcutaneous amifostine
Number of subjects: 60
Study: 9603657

Group type: EXPERIMENTAL
Intervention: Systemic liarozole 75 mg BID for at least 2 months
Number of subjects: 7
Study: 8160899

Group type: EXPERIMENTAL
Intervention: Aztreonam/Clindamycin (A/C)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Gentamicin/Clindamycin (G/C)
Number of subjects: 73
Study: 3415798

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Contracts
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pill packs
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Combination of techniques
Number of subjects: 112

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 112
Study: 31873765

Group type: EXPERIMENTAL
Intervention: Remimazolam besylate (0.025-0.4 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 100
Study: 29242294

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28950888

Group type: EXPERIMENTAL
Intervention: Web/DVD plus booklet intervention
Number of subjects: 168

Group type: COMPARATOR
Intervention: Booklet only (control group)
Number of subjects: 168
Study: 25794218

Group type: EXPERIMENTAL
Intervention: Balloon Kyphoplasty (BKP)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: High-viscosity cement vertebroplasty (HVCV)
Number of subjects: 107
Study: 23021013

Group type: EXPERIMENTAL
Intervention: 3 whole eggs/day (EGG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Yolk-free egg substitute (SUB)
Number of subjects: 37
Study: 21118743

Group type: EXPERIMENTAL
Intervention: Armodafinil 200 mg single dose
Number of subjects: 42

Group type: COMPARATOR
Intervention: Modafinil 200 mg single dose
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Multiple daily armodafinil 200 mg doses
Number of subjects: 42

Group type: COMPARATOR
Intervention: Multiple daily modafinil 200 mg doses
Number of subjects: 42
Study: 18256342

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Relaxation Training (RT)
Number of subjects: 72
Study: 16496124

Group type: EXPERIMENTAL
Intervention: Patellar tendon graft (PT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hamstring tendon graft (HT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Returned to sports
Number of subjects: 100

Group type: COMPARATOR
Intervention: Did not return to sports
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ceased sport activities
Number of subjects: 100
Study: 14687345

Group type: EXPERIMENTAL
Intervention: Group exercise (GE) intervention
Number of subjects: 551

Group type: COMPARATOR
Intervention: Flexibility and relaxation (FR) classes or no group activity (Control)
Number of subjects: 551
Study: 10847311

Group type: EXPERIMENTAL
Intervention: Integrated Group Therapy (IGT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No experimental treatment (control)
Number of subjects: 45
Study: 8635429

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) including carbamazepine (CBZ), phenytoin (PHT), phenobarbital (PB), valproate (VPA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated seizure patients
Number of subjects: 30
Study: 1406880

Group type: EXPERIMENTAL
Intervention: Acenocoumarol alone
Number of subjects: 120
Study: 3904437

Group type: EXPERIMENTAL
Intervention: Isoxicam 200 mg per day
Number of subjects: 3243

Group type: EXPERIMENTAL
Intervention: Isoxicam dosages ranging from 200 to 600 mg per day
Number of subjects: 3243
Study: 30790361

Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus rhamnosus and Bifidobacterium animalis subsp lactis)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 290
Study: 29183240

Group type: EXPERIMENTAL
Intervention: 6‐hr continuing education training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No e‐mail reminder
Number of subjects: 0

Group type: COMPARATOR
Intervention: E‐mail reminder
Number of subjects: 0
Study: 26670665

Group type: EXPERIMENTAL
Intervention: Tibolone (1.25 mg/day for 24 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (without hormone replacement therapy)
Number of subjects: 40
Study: 24561001

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (INFS)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Both INFS and FPNS
Number of subjects: 69
Study: 23107081

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel (3 mL placed 3 minutes prior to IUD insertion)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo gel (3 mL placed 3 minutes prior to IUD insertion)
Number of subjects: 200
Study: 20573150

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention combining outreach visits, reminders, and peer reviews implemented by a team of an obstetrician and a midwife.
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group with passive dissemination of the protocol.
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Intervention units' management practices.
Number of subjects: 106
Study: 17536049

Group type: EXPERIMENTAL
Intervention: Moving text (MT) therapy for two 4-week blocks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham therapy (spot the difference) for the first block, then crossed over to MT for the second block
Number of subjects: 19
Study: 16270403

Group type: EXPERIMENTAL
Intervention: IFN-alpha plus lamivudine (5 MU thrice per week + 100 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lamivudine only (100 mg daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IFN-alpha plus lamivudine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lamivudine only
Number of subjects: 50
Study: 12426861

Group type: EXPERIMENTAL
Intervention: Plant extracts (e.g., Serenoa repens, Pygeum Africanum, pumpkin seeds)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9973588

Group type: EXPERIMENTAL
Intervention: Motivational smoking cessation intervention
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1064
Study: 8528973

Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR) 0.5 mg/kg/day + L-folinic acid (L-FA) 10 mg/m2/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR) 0.525 mg/kg/day + L-folinic acid (L-FA) 10 mg/m2/day
Number of subjects: 14
Study: 2301050

Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics (cefoxitin)
Number of subjects: 2097

Group type: EXPERIMENTAL
Intervention: Age over 25 years
Number of subjects: 2097

Group type: EXPERIMENTAL
Intervention: Intraoperative antibiotics for gangrenous or perforated appendix
Number of subjects: 2097

Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics for perforation
Number of subjects: 2097

Group type: EXPERIMENTAL
Intervention: Patient delay (time from onset of symptoms till admission)
Number of subjects: 2097
Study: 76223

Group type: EXPERIMENTAL
Intervention: Active treatment group (25-50 mg hydrochlorothiazide and 50-100 mg triamterene daily, with half also receiving 250 mg to 2 g methyldopa daily)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 119
Study: 31682466

Group type: EXPERIMENTAL
Intervention: Fear appeal
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Personal appeal
Number of subjects: 315

Group type: COMPARATOR
Intervention: Social appeal
Number of subjects: 315
Study: 31403986

Group type: EXPERIMENTAL
Intervention: Family obligation stress measure
Number of subjects: 539
Study: 27914653

Group type: EXPERIMENTAL
Intervention: Warfarin therapy (target INR of 2.0 to 3.0)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Aspirin 150mg daily
Number of subjects: 370
Study: 25792206

Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham (SHAM)
Number of subjects: 24
Study: 23327487

Group type: EXPERIMENTAL
Intervention: Myo-inositol supplementation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 21640348

Group type: EXPERIMENTAL
Intervention: TMD+virgin olive oil (VOO)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Low-fat diet (control)
Number of subjects: 551
Study: 19490208

Group type: EXPERIMENTAL
Intervention: 10-U BoNTA
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: 20-U BoNTA
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 363
Study: 17039398

Group type: EXPERIMENTAL
Intervention: Multicomponent prevention program
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Early identification and resolution of perceived barriers
Number of subjects: 138
Study: 14971625

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard care plus a booklet
Number of subjects: 144
Study: 11129364

Group type: EXPERIMENTAL
Intervention: Higher-intensity home-based exercise
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Lower-intensity home-based exercise
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Higher-intensity class-based exercise
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group (0 or 1 major life event)
Number of subjects: 173
Study: 9614998

Group type: EXPERIMENTAL
Intervention: Enterosorbent 'Silard P'
Number of subjects: 36

Group type: COMPARATOR
Intervention: Generally-accepted complex therapy
Number of subjects: 36
Study: 8467568

Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 21
Study: 3897558

Group type: EXPERIMENTAL
Intervention: Oltipraz 15 mg/kg
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Oltipraz 20 mg/kg
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Oltipraz 25 mg/kg
Number of subjects: 294

Group type: COMPARATOR
Intervention: Single oral dose
Number of subjects: 294

Group type: COMPARATOR
Intervention: Divided dose taken 6 hours apart
Number of subjects: 294
Study: 30781461

Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) injection
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no PRP injection)
Number of subjects: 72
Study: 28432581

Group type: EXPERIMENTAL
Intervention: Immediate intravitreal Bevacizumab
Number of subjects: 40

Group type: COMPARATOR
Intervention: Deferred intravitreal Bevacizumab (after 3 months of observation)
Number of subjects: 40
Study: 26690010

Group type: EXPERIMENTAL
Intervention: Single medium culture in a time-lapse incubator (TLI) without renewal on day 3
Number of subjects: 59

Group type: COMPARATOR
Intervention: Two-step protocol
Number of subjects: 59

Group type: COMPARATOR
Intervention: Mixed group (embryos selected from both protocols)
Number of subjects: 59
Study: 24214232

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cinacalcet
Number of subjects: 0
Study: 23210586

Group type: COMPARATOR
Intervention: Chest wall proximity constraint (1 cm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No chest wall proximity constraint
Number of subjects: 0
Study: 19614962

Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 20
Study: 18042825

Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional etch and primer (AE)
Number of subjects: 60
Study: 16104039

Group type: EXPERIMENTAL
Intervention: Aprepitant regimen (Day 1: APR 125 mg, OND 8 mg, DEX 12 mg before chemotherapy and OND 8 mg 8 hrs later; Days 2-3: APR 80 mg every day)
Number of subjects: 866

Group type: COMPARATOR
Intervention: Control regimen (Day 1: OND 8 mg and DEX 20 mg before chemotherapy and OND 8 mg 8 hrs later; Days 2-3: OND 8 mg twice per day)
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Aprepitant regimen
Number of subjects: 866
Study: 12115238

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 0.15 mg/kg/week (increased to 0.25 mg/kg/week, max 15 mg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 98
Study: 10398353

Group type: EXPERIMENTAL
Intervention: Dysthymic disorder group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-depressed elderly group
Number of subjects: 40